所在位置: 人才队伍 >> 研究人员 >>
  • 黄振

教授,医药生物技术国家重点实验室 

地址:南京市栖霞区仙林大道163号,210023

邮箱:zhenhuang@nju.edu.cn









研究领域


炎性疾病发病机制探索

生物治疗策略研发



工作经历


2022.09-至今,南京大学,生命科学学院,教授

2015.09-2022-08,南京大学,生命科学学院,副教授

2013.07-2015-08,南京大学,生命科学学院,博士后



荣誉奖励


2019年,获南京大学新华报业优秀青年教师奖



代表性成果

[1] Chen Wang, Ziyu Shi, Yuqian Zhang, Mingyue Li , Jie Zhu, Zhen Huang*, Junfeng Zhang*, Jiangning Chen*. CBFβ promotes colorectal cancer progression through transcriptionally activating OPN, FAM129A, and UPP1 in a RUNX2-dependent manner. Cell Death Differ. 2021;28(11):3176-3192.     

[2] Fu Yong, Ni Junjun, Chen Jiahui, Ma Gailing, Zhao Mingming, Zhu Shuaidong, Shi Tongguo, Zhu Jie, Huang Zhen*, Zhang Junfeng*, Chen Jiangning*. Dual-Functionalized MSCs that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease. Mol Ther. 28:1214-1228, 2020.   

[3] Ma Junting, Yang Yaping, Fu Yong, Guo Feilong, Zhang Xiaoyi, Xiao Shuke, Zhu Weiming, Huang Zhen*, Zhang Junfeng*, Chen Jiangning*. PIAS3-mediated feedback loops promote chronic colitis-associated malignant transformation. Theranostics. 8:3022-3037, 2018. 

[4] Tu Tingyue, Yu Mao, Zhang Yanping, Shi Xiafei, Xu Jinhao, Hu Junqing, Gan Jingjing, He Wei, Dong Lei, Han Jianlin*, Huang Zhen*, Pan Yi, Zhang Junfeng. A novel fluorinated triazole derivative suppresses macrophage activation and alleviates experimental colitis via a Twist1-dependent pathway. Biochem Pharmacol. 155:275-287, 2018.   

[5] Fu Yong, Ma Junting, Shi Xiafei, Yang Yaping, Xiao Shuke, Li Jiahuang, Wei-Jin Gu*, Huang Zhen*, Zhang Junfeng, Chen Jiangning*. A novel pyrazole-containing indolizine derivative suppresses NF-kappa B activation and protects against TNBS-induced colitis via a PPAR-gamma-dependent pathway. Biochem Pharmacol. 135: 126-138, 2017. 

[6] Shi Tongguo, Xie Yin, Fu Yong, Zhou Qian, Ma Zirong, Ma Junting, Huang Zhen*, Zhang Junfeng*, Chen Jiangning*. The signaling axis of microRNA-31/interleukin-25 regulates Th1/Th17-mediated inflammation response in colitis. Mucosal Immunol. 10: 983-995, 2017. 

[7] Huang Zhen, Gan Jingjing, Long Ziyan, Guo Gguangxing, Shi Xiafei, Wang Chunming, Zang Yuhui, Ding Zhi, Chen Jiangning, Zhang Junfeng, Dong Lei. Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. Biomaterials. 90:72-84, 2016.  

[8] Huang Zhen, Ma Junting, Chen Mengjie, Jiang Haoyang, Fu Yong, Gan Jingjing, Dong Lei, Zhang Junfeng, Chen Jiangning. Dual TNF-alpha/IL-12p40 Interference as a Strategy to Protect Against Colitis Based on miR-16 Precursors With Macrophage Targeting Vectors. Mol Ther. 23:1611-21, 2015.   

[9] Huang Zhen,Gan Jingjing, Jia Lixin, Guo Guangxing, Wang Chunming, Ding Zhi, Zang Yuhui, Chen Jiangning, Dong Lei, Junfeng Zhang. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials. 48:26-36, 2015.  

[10]Huang Zhen, Shi Tongguo, Zhou Qian, Shi Song, Zhao Ran, Shi Hao, Dong Lei, Chenyu Zhang, Zeng Ke, Chen Jiangning, Zhang Junfeng. MiR-141 Regulates colonic leukocytic trafficking by targeting CXCL12beta during murine colitis and human Crohn's disease. Gut. 63:1247-57, 2014.